Theranexus: share price rises following promising trial results
Shortly before 12:00 pm, on At 10:40 am, shares in the Lyon-based biopharmaceutical company climbed by almost 10% in volumes representing more than 17 times their daily average over the last four trading sessions.
Data collected after 18 months in the phase 1/2 trial have demonstrated the potential of its Batten-1, with no significant progression of motor symptoms observed in six patients aged over 17.
For Mathieu Charvériat, Theranexus' CEO, this stabilization of motor symptom progression is a very encouraging signal for patients and their families.
The company says it is now considering various financing options to ensure it has adequate resources to launch a pivotal Phase 3 trial, the design of which has already been validated by the US FDA and the European EMA.
Juvenile Batten disease is a rare and fatal genetic disorder of the nervous system, for which there is currently no treatment.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction